|
1
|
MacRae EJ, Giannoudis A, Ryan R, Brown NJ,
Hamdy FC, Maitland N and Lewis CE: Gene therapy for prostate
cancer: Current strategies and new cell-based approaches. Prostate.
66:470–494. 2006. View Article : Google Scholar
|
|
2
|
Trojan L, Kiknavelidze K, Knoll T, Alken P
and Michel MS: Prostate cancer therapy: Standard management, new
options and experimental approaches. Anticancer Res. 25:551–561.
2005.PubMed/NCBI
|
|
3
|
Ward JF and Moul JW: Biochemical
recurrence after definitive prostate cancer therapy. Part I:
Defining and localizing biochemical recurrence of prostate cancer.
Curr Opin Urol. 15:181–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ward JF and Moul JW: Biochemical
recurrence after definitive prostate cancer therapy. Part II:
Treatment strategies for biochemical recurrence of prostate cancer.
Curr Opin Urol. 15:187–195. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Graaf M, Boven E, Scheeren HW, Haisma
HJ and Pinedo HM: Beta-glucuronidase-mediated drug release. Curr
Pharm Des. 8:1391–1403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Houba PH, Boven E, van der Meulen-Muileman
IH, Leenders RG, Scheeren JW, Pinedo HM and Haisma HJ: Pronounced
antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3
in combination with a monoclonal antibody beta-glucuronidase
conjugate. Int J Cancer. 91:550–554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Houba PH, Boven E, van der Meulen-Muileman
IH, Leenders RG, Scheeren JW, Pinedo HM and Haisma HJ: A novel
doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective
chemotherapy: Distribution and efficacy in experimental human
ovarian cancer. Br J Cancer. 84:550–557. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Dillen IJ, Mulder NH, Vaalburg W, de
Vries EF and Hospers GA: Influence of the bystander effect on
HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mesnil M and Yamasaki H: Bystander effect
in herpes simplex virus-thymidine kinase/ganciclovir cancer gene
therapy: Role of gap-junctional intercellular communication. Cancer
Res. 60:3989–3999. 2000.PubMed/NCBI
|
|
10
|
Fonseca MJ, Storm G, Hennink WE, Gerritsen
WR and Haisma J: Cationic polymeric gene delivery of
beta-glucuronidase for doxorubicin prodrug therapy. J Gene Med.
1:407–414. 1999. View Article : Google Scholar
|
|
11
|
de Graaf M, Boven E, Oosterhoff D, van der
Meulen-Muileman IH, Huls GA, Gerritsen WR, Haisma HJ and Pinedo HM:
A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein
for selective chemotherapy with a glucuronide prodrug. Br J Cancer.
86:811–818. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei G, Loktionova NA, Pegg AE and Moschel
RC: Beta-glucuronidase-cleavable prodrugs of
O6-benzylguanine and
O6-benzyl-2′-deoxyguanosine. J Med Chem. 48:256–261.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Houba PH, Boven E, Erkelens CA, Leenders
RG, Scheeren JW, Pinedo HM and Haisma HJ: The efficacy of the
anthracycline prodrug daunorubicin-GA3 in human ovarian cancer
xenografts. Br J Cancer. 78:1600–1606. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sperker B, Werner U, Mürdter TE, Tekkaya
C, Fritz P, Wacke R, Adam U, Gerken M, Drewelow B and Kroemer HK:
Expression and function of beta-glucuronidase in pancreatic cancer:
Potential role in drug targeting. Naunyn Schmiedebergs Arch
Pharmacol. 362:110–115. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park HS, Cheon J, Cho HY, Ko YH, Bae JH,
Moon DG and Kim JJ: In vivo characterization of a prostate-specific
antigen promoter-based suicide gene therapy for the treatment of
benign prostatic hyperplasia. Gene Ther. 10:1129–1134. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu D, Chen D, Chiu C, Razmazma B, Chow YH
and Pang S: Prostate-specific targeting using PSA promoter-based
lentiviral vectors. Cancer Gene Ther. 8:628–635. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin T, Gu J, Zhang L, Huang X, Stephens
LC, Curley SA and Fang B: Targeted expression of green fluorescent
protein/tumor necrosis factor-related apoptosis-inducing ligand
fusion protein from human telomerase reverse transcriptase promoter
elicits antitumor activity without toxic effects on primary human
hepatocytes. Cancer Res. 62:3620–3625. 2002.PubMed/NCBI
|
|
18
|
Nasu Y, Kusaka N, Saika T, Tsushima T and
Kumon H: Suicide gene therapy for urogenital cancer: Current
outcome and prospects. Mol Urol. 4:67–71. 2000. View Article : Google Scholar
|
|
19
|
Yazawa K, Fisher WE and Brunicardi FC:
Current progress in suicide gene therapy for cancer. World J Surg.
26:783–789. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Poulsen TT, Pedersen N and Poulsen HS:
Replacement and suicide gene therapy for targeted treatment of lung
cancer. Clin Lung Cancer. 6:227–236. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nicholas TW, Read SB, Burrows FJ and Kruse
CA: Suicide gene therapy with herpes simplex virus thymidine kinase
and ganciclovir is enhanced with connexins to improve gap junctions
and bystander effects. Histol histopathol. 18:495–507.
2003.PubMed/NCBI
|
|
22
|
Fillat C, Carrió M, Cascante A and Sangro
B: Suicide gene therapy mediated by the herpes simplex virus
thymidine kinase gene/ganciclovir system: Fifteen years of
application. Curr Gene Ther. 3:13–26. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Satoh T, Irie A, Egawa S and Baba S: In
situ gene therapy for prostate cancer. Curr Gene Ther. 5:111–119.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shalev M, Kadmon D, Teh BS, Butler EB,
Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT
and Miles BJ: Suicide gene therapy toxicity after multiple and
repeat injections in patients with localized prostate cancer. J
Urol. 163:1747–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Biela BH, Khawli LA, Hu P and Epstein AL:
Chimeric TNT-3/human beta-glucuronidase fusion proteins for
antibody-directed enzyme prodrug therapy (ADEPT). Cancer Biother
Radiopharm. 18:339–353. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haisma HJ, Sernee MF, Hooijberg E,
Brakenhoff RH, vd Meulen-Muileman IH, Pinedo HM and Boven E:
Construction and characterization of a fusion protein of
single-chain anti-CD20 antibody and human beta-glucuronidase for
antibody-directed enzyme prodrug therapy. Blood. 92:184–190.
1998.PubMed/NCBI
|
|
27
|
Kaliberov SA, Chiz S, Kaliberova LN,
Krendelchtchikova V, Della Manna D, Zhou T and Buchsbaum DJ:
Combination of cytosine deaminase suicide gene expression with DR5
antibody treatment increases cancer cell cytotoxicity. Cancer Gene
Ther. 13:203–214. 2006. View Article : Google Scholar
|
|
28
|
Djeha HA, Todryk SM, Pelech S, Wrighton
CJ, Irvine AS, Mountain A and Lipinski KS: Antitumor immune
responses mediated by adenoviral GDEPT using nitroreductase/CB1954
is enhanced by high-level coexpression of heat shock protein 70.
Cancer Gene Ther. 12:560–571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miki K, Xu M, Gupta A, Ba Y, Tan Y,
Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR and Hoffman RM:
Methioninase cancer gene therapy with selenomethionine as suicide
prodrug substrate. Cancer Res. 61:6805–6810. 2001.PubMed/NCBI
|
|
30
|
Denny WA: Prodrugs for gene-directed
enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol.
2003:48–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dabrowska A, Szary J, Kowalczuk M, Szala S
and Ugorski M: CEA-negative glioblastoma and melanoma cells are
sensitive to cytosine deaminase/5-fluorocytosine therapy directed
by the carcinoembryonic antigen promoter. Acta Biochim Pol.
51:723–732. 2004.PubMed/NCBI
|
|
32
|
Ikegami S, Tadakuma T, Suzuki S, Yoshimura
I, Asano T and Hayakawa M: Development of gene therapy using
prostate-specific membrane antigen promoter/enhancer with Cre
Recombinase/LoxP system for prostate cancer cells under androgen
ablation condition. Jpn J Cancer Res. 93:1154–1163. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng W, Chen J, Huang YH and Sawicki JA:
Tightly-regulated suicide gene expression kills PSA-expressing
prostate tumor cells. Gene Ther. 12:1573–1580. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qiao J, Doubrovin M, Sauter BV, Huang Y,
Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH,
et al: Tumor-specific transcriptional targeting of suicide gene
therapy. Gene Ther. 9:168–175. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ueda K, Iwahashi M, Nakamori M, Nakamura
M, Matsuura I, Yamaue H and Tanimura H: Carcinoembryonic
antigen-specific suicide gene therapy of cytosine
deaminase/5-fluorocytosine enhanced by the cre/loxP system in the
orthotopic gastric carcinoma model. Cancer Res. 61:6158–6162.
2001.PubMed/NCBI
|
|
36
|
Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA
and Fang B: Augmenting transgene expression from carcinoembryonic
antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther.
3:278–283. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ray S, Paulmurugan R, Hildebrandt I, Iyer
M, Wu L, Carey M and Gambhir SS: Novel bidirectional vector
strategy for amplification of therapeutic and reporter gene
expression. Hum Gene Ther. 15:681–690. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iyer M, Salazar FB, Lewis X, Zhang L, Wu
L, Carey M and Gambhir SS: Non-invasive imaging of a transgenic
mouse model using a prostate-specific two-step transcriptional
amplification strategy. Transgenic Res. 14:47–55. 2005. View Article : Google Scholar : PubMed/NCBI
|
